Cargando…

A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin‐Based Chemotherapy‐Induced Nausea and Vomiting in Japan

BACKGROUND: We previously reported the results of a prospective study of chemotherapy‐induced nausea and vomiting (CINV) in a cohort of patients who received carboplatin‐based chemotherapy and were selected from a nationwide registry of those scheduled for moderately (MEC) or highly emetogenic chemo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iihara, Hirotoshi, Shimokawa, Mototsugu, Hayashi, Toshinobu, Kawazoe, Hitoshi, Saeki, Toshiaki, Aiba, Keisuke, Tamura, Kazuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2019
Materias:	Symptom Management and Supportive Care
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011617/ https://www.ncbi.nlm.nih.gov/pubmed/32043774 http://dx.doi.org/10.1634/theoncologist.2019-0292

Ejemplares similares

Low‐Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin‐Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial
por: Sakai, Chizuru, et al.
Publicado: (2021)

Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
por: Hayashi, Toshinobu, et al.
Publicado: (2021)

One-Day Versus Three-Day Dexamethasone with NK1RA for Patients Receiving Carboplatin and Moderate Emetogenic Chemotherapy: A Network Meta-analysis
por: Watanabe, Daichi, et al.
Publicado: (2022)

A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy‐Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2021)

Quality of Life Associated with Nausea and Vomiting from Anthracycline‐Based Chemotherapy: A Pooled Data Analysis from Three Prospective Trials
por: Yeo, Winnie, et al.
Publicado: (2021)

Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis
por: Aogi, Kenjiro, et al.
Publicado: (2020)

Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy‐Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial
por: van der Vorst, Maurice J.D.L., et al.
Publicado: (2020)

One‐Day Versus Three‐Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy‐Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data‐Based Meta‐Analysis
por: Okada, Yuki, et al.
Publicado: (2019)

Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy‐Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602)
por: Navari, Rudolph M, et al.
Publicado: (2023)

5HT(3)RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy‐induced nausea and vomiting in colorectal cancer
por: Hayashi, Toshinobu, et al.
Publicado: (2020)

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
por: Shimokawa, Mototsugu, et al.
Publicado: (2022)

Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B)
por: Ozeki, Rie, et al.
Publicado: (2022)

Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial
por: Iihara, Hirotoshi, et al.
Publicado: (2019)

Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients
por: Iihara, Hirotoshi, et al.
Publicado: (2019)

Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials
por: Yamamoto, Senri, et al.
Publicado: (2021)

Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary
por: Takeuchi, Hideki, et al.
Publicado: (2015)

Age and Gender Moderate the Impact of Early Palliative Care in Metastatic Non-Small Cell Lung Cancer
por: Nipp, Ryan D., et al.
Publicado: (2016)

Use of Palliative Care Services in a Tertiary Cancer Center
por: Dalal, Shalini, et al.
Publicado: (2016)

Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors
por: Hofheinz, Ralf-Dieter, et al.
Publicado: (2016)

Development of Palliative Care in China: A Tale of Three Cities
por: Yin, Zhenyu, et al.
Publicado: (2017)

Effects of Early Integrated Palliative Care on Caregivers of Patients with Lung and Gastrointestinal Cancer: A Randomized Clinical Trial
por: El‐Jawahri, Areej, et al.
Publicado: (2017)

Sarcopenia Is Associated with Quality of Life and Depression in Patients with Advanced Cancer
por: Nipp, Ryan D., et al.
Publicado: (2017)

A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS–Cancer‐Associated Thrombosis Study
por: Gerotziafas, Grigoris T., et al.
Publicado: (2017)

Use of Antidepressant Medications Moderates the Relationship Between Depressive Symptoms and Hospital Length of Stay in Patients with Advanced Cancer
por: Wong, Risa L., et al.
Publicado: (2018)

Pattern and Predictors of Outpatient Palliative Care Referral Among Thoracic Medical Oncologists
por: Hui, David, et al.
Publicado: (2018)

Phase Angle and the Diagnosis of Impending Death in Patients with Advanced Cancer: Preliminary Findings
por: Hui, David, et al.
Publicado: (2018)

Patient‐Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia
por: El‐Jawahri, Areej, et al.
Publicado: (2018)

Permanent Chemotherapy‐Induced Alopecia in Patients with Breast Cancer: A 3‐Year Prospective Cohort Study
por: Kang, Danbee, et al.
Publicado: (2018)

A Prospective Observational Study on Effect of Short‐Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO‐01)
por: Nakamura, Michio, et al.
Publicado: (2017)

Hepatosplenic Candidiasis Without Prior Documented Candidemia: An Underrecognized Diagnosis?
por: van Prehn, Joffrey, et al.
Publicado: (2017)

Implementation of the Edmonton Symptom Assessment System for Symptom Distress Screening at a Community Cancer Center: A Pilot Program
por: Hui, David, et al.
Publicado: (2017)

Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review
por: Hui, David, et al.
Publicado: (2016)

The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities
por: Klesse, Laura J., et al.
Publicado: (2020)

Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow‐Up Survey
por: Kakkar, Ajay K., et al.
Publicado: (2020)

Eflapegrastim, a Long‐Acting Granulocyte‐Colony Stimulating Factor for the Management of Chemotherapy‐Induced Neutropenia: Results of a Phase III Trial
por: Schwartzberg, Lee S., et al.
Publicado: (2020)

Impact on Health‐Related Quality of Life of Parenteral Nutrition for Patients with Advanced Cancer Cachexia: Results from a Randomized Controlled Trial
por: Bouleuc, Carole, et al.
Publicado: (2020)

The EORTC QLQ‐C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the “Real‐World”: Results from the Population‐Based PROFILES Registry
por: Husson, Olga, et al.
Publicado: (2019)

A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor‐Induced Skin Toxicities
por: Kim, Young Saing, et al.
Publicado: (2019)

Ambulation Recovery After Surgery for Metastases to the Femur
por: Kim, Yongsung, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9r7dsudbvfnoa1bfv457scqttq